Gelonghui May 3| Lillybaccaratanalysis.US) fell 3% to 733baccaratanalysis.27 dollars. on the news frontbaccaratanalysisAmgen's mid-term trial of a new weight-loss drug receives positive data. If the drug is approved, it will compete with Novo NordiskbaccaratanalysisWegovy and Lilly's Zepbound compete. Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.
